Hepatitis B Virus Reactivation and Antiviral Prophylaxis Practices in Patients with Malignancies Receiving Chemotherapy: A Real-World Retrospective Study

Background and Objectives: Hepatitis B virus (HBV) reactivation is a potentially life-threatening complication in patients receiving chemotherapy and immunosuppressive therapy. Real-world data regarding reactivation despite antiviral prophylaxis remain limited. Materials and Methods: We retrospectively evaluated patients with malignancies who received chemotherapy at Kocaeli University Faculty of Medicine Hospital between 2013 and 2017. Demographic characteristics, malignancy type, virological markers, laboratory findings, chemotherapy regimens, antiviral prophylaxis strategies, and HBV reactivation rates were analyzed. Results: A total of 294 patients were included in this study, of whom 18 (6.1%) experienced HBV reactivation. Reactivation was significantly more common in patients with hematologic malignancies (11.1%) than in patients with solid tumors (3.2%). Bone marrow transplantation was associated with a higher observed frequency of HBV reactivation. HBV reactivation was observed in a subset of patients receiving antiviral prophylaxis. Delayed initiation of antiviral treatment and irregular antiviral use were documented in some patients who developed HBV reactivation. Conclusions: Malignancies and intensive immunosuppressive therapies were associated with an increased risk of HBV reactivation despite prophylactic strategies. The results of our study also highlight the importance of HBV screening before chemotherapy, timely initiation of potent antiviral prophylaxis, and extended post-treatment monitoring in high-risk populations.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-16
DOI
https://doi.org/10.3390/medicina62112245
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatitis B Virus Reactivation and Antiviral Prophylaxis Practices in Patients with Malignancies Receiving Chemotherapy: A Real-World Retrospective Study

Umut Kefeli, Hayrunnisa Albayrak, Pınar Tarkun, Devrim Çabuk et al.
1 links
Medicina
Hepatitis B Virus Studies
article

Hepatitis B Virus Reactivation and Antiviral Prophylaxis Practices in Patients with Malignancies Receiving Chemotherapy: A Real-World Retrospective Study

Umut Kefeli, Hayrunnisa Albayrak, Pınar Tarkun, Devrim Çabuk, Kazım Uygun, Fatma Tuğba Çatan Erdekli
article en

Abstract

Background and Objectives: Hepatitis B virus (HBV) reactivation is a potentially life-threatening complication in patients receiving chemotherapy and immunosuppressive therapy. Real-world data regarding reactivation despite antiviral prophylaxis remain limited. Materials and Methods: We retrospectively evaluated patients with malignancies who received chemotherapy at Kocaeli University Faculty of Medicine Hospital between 2013 and 2017. Demographic characteristics, malignancy type, virological markers, laboratory findings, chemotherapy regimens, antiviral prophylaxis strategies, and HBV reactivation rates were analyzed. Results: A total of 294 patients were included in this study, of whom 18 (6.1%) experienced HBV reactivation. Reactivation was significantly more common in patients with hematologic malignancies (11.1%) than in patients with solid tumors (3.2%). Bone marrow transplantation was associated with a higher observed frequency of HBV reactivation. HBV reactivation was observed in a subset of patients receiving antiviral prophylaxis. Delayed initiation of antiviral treatment and irregular antiviral use were documented in some patients who developed HBV reactivation. Conclusions: Malignancies and intensive immunosuppressive therapies were associated with an increased risk of HBV reactivation despite prophylactic strategies. The results of our study also highlight the importance of HBV screening before chemotherapy, timely initiation of potent antiviral prophylaxis, and extended post-treatment monitoring in high-risk populations.

MedicinaVol. 62(11)
Kocaeli Üniversitesi (TR), Hacettepe University (TR)
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon